RPRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RPRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of Royalty Pharma is: Moderate Risk: Sensitive, better choose undervalued stock.
For the Biotechnology subindustry, Royalty Pharma's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Royalty Pharma's Risk Assessment distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's Risk Assessment falls into.
Royalty Pharma (NAS:RPRX) Risk Assessment Explanation
Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Thank you for viewing the detailed overview of Royalty Pharma's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Rory B Riggs | director | 65 RAILROAD AVE, RIDGEFIELD NJ 07657 |
Avara Management Ltd | 10 percent owner | C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900 |
Terrance P. Coyne | officer: EVP & CFO | C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022 |
Pablo G. Legorreta | director, officer: CEO, Chairman of the Board | 110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022 |
George W. Lloyd | officer: EVP, Investments & GC | C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022 |
Marshall Urist | officer: EVP, Research & Investments | C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022 |
Mario Germano Giuliani | director, 10 percent owner | C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900 |
James F. Reddoch | officer: EVP, Research & Investments | C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022 |
Nogra Group Sicaf Sif Gg Strategic | 10 percent owner | C/O NOGRA GROUP SICAF-SIF S.A., 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227 |
Nogra Group Sicaf - Sif S.a. | 10 percent owner | 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227 |
Catherine M. Engelbert | director | 110 NORTH CARPENTER STREET, CHICAGO IL 60607 |
Errol B Desouza | director | 215 COLLEGE ROAD, PARAMUS NJ 07652 |
Henry A Fernandez | director | MSCI INC., 88 PINE STREET, NEW YORK NY 10005 |
Gregory Norden | director | 16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005 |
Ted W Love | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By sperokesalga sperokesalga • 05-03-2023
By GuruFocus Research • 05-25-2023
By sperokesalga sperokesalga • 03-01-2023
By Stock market mentor Stock market mentor • 01-09-2023
By Marketwired • 09-05-2023
By GuruFocus Research GuruFocus Editor • 02-20-2023
By Marketwired • 09-05-2023
By sperokesalga sperokesalga • 04-13-2023
By sperokesalga sperokesalga • 06-07-2023
By GuruFocus Research GuruFocus Editor • 05-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.